Christine C. Lee

Christine C. Lee

Auto-generated profile, based on publicly available information

Christine C. Lee

Enteric Diseases Laboratory Branch, Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KSKrishna Chaitanya Suddala
Krishna Chaitanya Suddala
CLChristine C Lee
Christine C Lee
PMPaul Meraner
Paul Meraner
MMMariana Marin
Mariana Marin
RMRuben M Markosyan
Ruben M Markosyan
Gregory MelikyanGregory Melikyan
Gregory Melikyan
Late endosome-resident interferon-induced transmembrane protein 3 (IFITM3) inhibits fusion of diverse viruses, including Influenza A virus (IAV), by a poorly understood mechanism. Despite the broad antiviral activity of IFITM3, viruses like Lassa virus (LASV), are fully resistant to its inhibitory effects. It is currently unclear whether resistance arises from a highly efficient fusion machinery that is capable of overcoming IFITM3 restriction or the ability to enter from cellular sites devoid of this factor. Here, we constructed and validated a functional IFITM3 tagged with EGFP or other fluorescent proteins. This breakthrough allowed live cell imaging of virus co-trafficking and fusion with endosomal compartments in cells expressing fluorescent IFITM3. Three-color single virus and endosome tracking revealed that sensitive (IAV), but not resistant (LASV), viruses become trapped within IFITM3-positive endosomes where they underwent hemifusion but failed to release their content into the cytoplasm. IAV fusion with IFITM3-containing compartments could be rescued by amphotericin B treatment, which has been previously shown to antagonize the antiviral activity of this protein. By comparison, virtually all LASV particles trafficked and fused with endosomes lacking detectable levels of fluorescent IFITM3, implying that this virus escapes restriction by utilizing endocytic pathways that are distinct from the IAV entry pathways. The importance of virus uptake and transport pathways is further reinforced by the observation that LASV glycoprotein-mediated cell-cell fusion is inhibited by IFITM3 and other members of the IFITM family expressed in target cells. Together, our results strongly support a model according to which IFITM3 accumulation at the sites of virus fusion is a prerequisite for its antiviral activity and that this protein traps viral fusion at a hemifusion stage by preventing the formation of fusion pores. We conclude that the ability to utilize alternative endocytic pathways for entry confers IFITM3-resistance to otherwise sensitive viruses. Expression of interferon-induced transmembrane proteins (IFITMs) in target cells potently inhibits fusion of many unrelated enveloped viruses, including the Influenza A virus, whereas arenaviruses, such as the Lassa fever virus, are resistant to these factors. The mechanism by which IFITMs interfere with the viral fusion step and the mechanism of virus escape from these restriction factors are poorly understood. Here, we tagged the late endosome-resident IFITM3 with fluorescent proteins and visualized single virus entry and fusion with endosomes in living cells expressing these constructs. Single virus and endosome tracking experiments demonstrate that the sensitive Influenza A virus is trapped within acidic IFITM3-positive endosomes that are not permissive for viral fusion. In contrast, the resistant Lassa virus consistently enters and fuses with endosomes lacking IFITM3. Our results imply that accumulation of IFITM3 in virus-carrying endosomes is a prerequisite for blocking fusion of diverse enveloped viruses and that viruses insensitive to this protein escape restriction by entering through distinct endosomal trafficking pathways that do not converge with IFITM3-positive compartments.

3 March 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
JHJulia C Haston
Julia C Haston
SMShanna Miko
Shanna Miko
JCJennifer R Cope
Jennifer R Cope
HMHaley McKeel
Haley McKeel
CWCynney Walters
Cynney Walters
CLChristine C Lee
Christine C Lee
This report describes detection of Cronobacter sakazakii in two infants linked to powdered infant formula and breast pump equipment.

8 March 2018 in eLife
Verified
Journal Article
Open access
CLChristine C Lee
Christine C Lee
BLBing Li
Bing Li
HYHongtao Yu
Hongtao Yu
MMMichael J. Matunis
Michael J. Matunis
The Anaphase Promoting Complex/Cyclosome (APC/C) is a ubiquitin E3 ligase that functions as the gatekeeper to mitotic exit. APC/C activity is controlled by an interplay of multiple pathways during mitosis, including the spindle assembly checkpoint (SAC), that are not yet fully understood. Here, we show that sumoylation of the APC4 subunit of the APC/C peaks during mitosis and is critical for timely APC/C activation and anaphase onset. We have also identified a functionally important SUMO interacting motif in the cullin-homology domain of APC2 located near the APC4 sumoylation sites and APC/C catalytic core. Our findings provide evidence of an important regulatory role for SUMO modification and binding in affecting APC/C activation and mitotic exit.

13 December 2022 in Vaccine
Verified
Journal Article
Open access
PSPhillip P. Salvatore
Phillip P. Salvatore
CLChristine C. Lee
Christine C. Lee
SSSadia Sleweon
Sadia Sleweon
DMDavid W. McCormick
David W. McCormick
LNLavinia Nicolae
Lavinia Nicolae
LHLiesl M. Hagan
Liesl M. Hagan
The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons. Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis. A total of 957 specimens were provided by 93 participants, of whom 78 (84 %) were vaccinated and 17 (16 %) were unvaccinated. No significant differences were detected in duration of RT-PCR positivity among vaccinated participants (median: 13 days) versus those unvaccinated (median: 13 days; p = 0.50), or in duration of culture positivity (medians: 5 days and 5 days; p = 0.29). Among vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p = 0.048) or Janssen (p = 0.003) vaccine recipients. In post-hoc analyses, Moderna vaccine recipients demonstrated significantly shorter duration of culture positivity compared to unvaccinated participants (p = 0.02). When restricted to participants without reported prior infection, the difference between Moderna vaccine recipients and unvaccinated participants was more pronounced (medians: 3 days and 6 days, p = 0.002). Infectious periods for vaccinated and unvaccinated persons who become infected with SARS-CoV-2 are similar and can be highly variable, though some vaccinated persons are likely infectious for shorter durations. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks. In such settings, clinicians and public health practitioners should consider vaccinated, infected persons to be no less infectious than unvaccinated, infected persons.

14 September 2022 in International Journal of Systematic and Evolutionary Microbiology
Verified
Journal Article
Open access
MIMohammad Islam
Mohammad Islam
KLKevin Liang
Kevin Liang
FOFabini Orata
Fabini Orata
MIMonica S. Im
Monica S. Im
MAMunirul Alam
Munirul Alam
Yann F. BoucherYann F. Boucher
Yann F. Boucher
A number of bacteria with close resemblance to Vibrio cholerae have been isolated over the years by the Centres for Disease Control and Prevention (CDC), which could not be assigned a proper taxonomic designation on the basis of the results from preliminary identification methods. Nine such isolates have been found to share 16S rRNA gene identity exceeding 99 % with V. cholerae, yet DNA–DNA hybridization (60.4–62.1 %) and average nucleotide identity values (94.4–95.1 %) were below the species cut-off, indicating a potentially novel species. Phylogenetic analysis of core genomes places this group of isolates in a monophyletic clade, within the ‘Cholerae clade’, but distinct from any other species. Extensive phenotypic characterization reveals unique biochemical properties that distinguish this novel species from V. cholerae . Comparative genomic analysis reveals a unique set of siderophore genes, indicating that iron acquisition strategies could be vital for the divergence of the novel species from a common ancestor with V. cholerae . On the basis of the genetic, phylogenetic and phenotypic differences observed, we propose that these isolates represent a novel species of the genus Vibrio , for which the name Vibrio tarriae sp. nov. is proposed. Strain 2521-89 T (= DSM 112461=CCUG 75318), isolated from lake water, is the type strain.

21 November 2022 in Toxins
Verified
Journal Article
Open access
PDF file
BCBrady Cunningham
Brady Cunningham
RWRebekah Wharton
Rebekah Wharton
CLChristine Lee
Christine Lee
MMMike A. Mojica
Mike A. Mojica
LKLogan C. Krajewski
Logan C. Krajewski
EHElizabeth I Hamelin
Elizabeth I Hamelin
Microcystins are toxic chemicals generated by certain freshwater cyanobacteria. These chemicals can accumulate to dangerous levels during harmful algal blooms. When exposed to microcystins, humans are at risk of hepatic injury, including liver failure. Here, we describe a method to detect microcystins in human plasma by using immunocapture followed by a protein phosphatase inhibition assay. At least 279 microcystins have been identified, and most of these compounds share a common amino acid, the Adda side chain. We targeted this Adda side chain using a commercial antibody and extracted microcystins from human samples for screening and analysis. To quantitate the extracted microcystins, we fortified plasma with microcystin-LR, one of the most well-studied, commonly detected, and toxic microcystin congeners. The quantitation range for the detection of microcystin in human plasma using this method is 0.030–0.50 ng/mL microcystin-LR equivalents. This method detects unconjugated and conjugated forms (cysteine and glutathione) of microcystins. Quality control sample accuracies varied between 98.9% and 114%, with a precision of 7.18–15.8%. Finally, we evaluated plasma samples from a community health surveillance project of Florida residents living or working near harmful algae blooms.